Biomea Fusion Inc Total Assets
Biomea Fusion Inc total assets. Based on the latest financial reports, Biomea Fusion Inc (BMEA) holds total assets worth $46.38 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see BMEA stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Biomea Fusion Inc (2019–2025)
Total assets of Biomea Fusion Inc from 2019 to 2025. This chart illustrates how Biomea Fusion Inc's total assets have evolved over time, based on quarterly financial data. See Biomea Fusion Inc (BMEA) stock price for real-time trading data and today's change.
Biomea Fusion Inc - Asset Composition Analysis
Biomea Fusion Inc Total Assets Breakdown (December 2025)
Biomea Fusion Inc total assets breakdown as of December 2025. Biomea Fusion Inc's total assets of $46.38 Million consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Biomea Fusion Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Biomea Fusion Inc (BMEA) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomea Fusion Inc's current assets represent 99.1% of total assets in 2025, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 95.3% of total assets in 2025, up from 90.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Biomea Fusion Inc Competitors by Total Assets
Key competitors of Biomea Fusion Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Biomea Fusion Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.98 | 2.25 | 40.57 |
| Quick Ratio | 4.98 | 2.25 | 40.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $37.02 Million | $24.87 Million | $195.58 Million |
Biomea Fusion Inc - Advanced Valuation Insights
This section examines the relationship between Biomea Fusion Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.63 |
| Latest Market Cap to Assets Ratio | 0.77 |
| Asset Growth Rate (YoY) | -26.7% |
| Total Assets | $58.57 Million |
| Market Capitalization | $45.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biomea Fusion Inc's assets below their book value (0.77x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biomea Fusion Inc's assets decreased by 26.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biomea Fusion Inc (2019–2025)
The table below shows the annual total assets of Biomea Fusion Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $58.57 Million | -26.73% |
| 2024-12-31 | $79.94 Million | -60.02% |
| 2023-12-31 | $199.93 Million | +54.61% |
| 2022-12-31 | $129.31 Million | -30.37% |
| 2021-12-31 | $185.71 Million | +197.00% |
| 2020-12-31 | $62.53 Million | +23494.72% |
| 2019-12-31 | $265.00K | -- |
About Biomea Fusion Inc
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase I… Read more